A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived MN HIV-1 Recombinant Envelope Glycoprotein (rgp160) of Human Immunodeficiency Virus at Two Different Vaccination Schedules

NCT00001043 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

20

Enrollment

NIH

Sponsor class

Conditions

HIV Infections
HIV Seronegativity

Interventions

BIOLOGICAL: gp160 Vaccine (Immuno-AG)

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)